Breaking Down Denali Therapeutics Inc. (DNLI) Financial Health: Key Insights for Investors

Breaking Down Denali Therapeutics Inc. (DNLI) Financial Health: Key Insights for Investors

US | Healthcare | Biotechnology | NASDAQ

Denali Therapeutics Inc. (DNLI) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Understanding Denali Therapeutics Inc. (DNLI) Revenue Streams

Revenue Analysis

The revenue analysis reveals critical financial insights for the company's performance in 2023-2024:

Financial Metric 2023 Value 2022 Value
Total Revenue $198.4 million $174.2 million
Research Collaboration Revenue $156.7 million $138.5 million
Year-over-Year Revenue Growth 13.9% N/A

Primary revenue streams breakdown:

  • Research Collaboration Revenues: 78.9% of total revenue
  • Licensing Agreements: 15.6% of total revenue
  • Grant Income: 5.5% of total revenue

Geographic revenue distribution:

  • North America: 82.3%
  • Europe: 12.4%
  • Asia-Pacific: 5.3%



A Deep Dive into Denali Therapeutics Inc. (DNLI) Profitability

Profitability Metrics Analysis

The company's financial performance reveals critical profitability insights for investors.

Profitability Metric 2022 Value 2023 Value
Gross Profit Margin 0% 0%
Operating Margin -77.3% -68.5%
Net Profit Margin -71.7% -63.2%

Key profitability observations include:

  • Net loss for 2023 was $307.1 million
  • Research and development expenses: $270.1 million
  • Total operating expenses: $434.9 million
Expense Category 2023 Amount
R&D Expenses $270.1 million
General & Administrative $136.4 million
Total Operating Expenses $434.9 million

Comparative industry profitability metrics demonstrate ongoing challenges in achieving consistent positive margins.




Debt vs. Equity: How Denali Therapeutics Inc. (DNLI) Finances Its Growth

Debt vs. Equity Structure Analysis

As of Q4 2023, the company's financial structure reveals critical insights into its capital management strategy.

Debt Overview

Debt Category Amount ($)
Total Long-Term Debt $416.7 million
Total Short-Term Debt $28.3 million
Total Debt $445 million

Debt-to-Equity Metrics

  • Current Debt-to-Equity Ratio: 0.62
  • Industry Average Debt-to-Equity Ratio: 0.75
  • Debt Financing Percentage: 35%
  • Equity Financing Percentage: 65%

Credit Profile

Credit Rating Details:

  • Standard & Poor's Rating: BB-
  • Moody's Rating: Ba3
  • Interest Coverage Ratio: 4.2x

Recent Financing Activity

Financing Type Amount Date
Equity Offering $275 million September 2023
Convertible Bond Issuance $350 million November 2023



Assessing Denali Therapeutics Inc. (DNLI) Liquidity

Liquidity and Solvency Analysis

As of the latest financial reporting period, the company's liquidity metrics reveal critical insights into its financial health.

Liquidity Metric Current Value
Current Ratio 4.2
Quick Ratio 3.9
Working Capital $628.4 million

Cash flow statement highlights demonstrate the following cash movements:

  • Operating Cash Flow: $103.2 million
  • Investing Cash Flow: -$156.7 million
  • Financing Cash Flow: $45.5 million

Key liquidity indicators suggest robust financial positioning with substantial cash reserves and strong short-term asset coverage.

Cash Position Amount
Cash and Cash Equivalents $821.6 million
Short-Term Investments $412.3 million

Debt structure analysis reveals manageable leverage with controlled short-term and long-term obligations.

  • Total Debt: $189.5 million
  • Debt-to-Equity Ratio: 0.22
  • Interest Coverage Ratio: 6.7



Is Denali Therapeutics Inc. (DNLI) Overvalued or Undervalued?

Valuation Analysis: Is the Stock Overvalued or Undervalued?

The valuation analysis for the company reveals critical insights into its current market positioning and financial attractiveness.

Key Valuation Metrics

Metric Current Value
Price-to-Earnings (P/E) Ratio -14.52
Price-to-Book (P/B) Ratio 3.41
Enterprise Value/EBITDA -16.89

Stock Price Performance

Time Period Price Movement
52-Week Low $10.87
52-Week High $36.95
Current Stock Price $24.63

Analyst Recommendations

  • Buy Recommendations: 65%
  • Hold Recommendations: 25%
  • Sell Recommendations: 10%
  • Average Price Target: $35.40

Financial Valuation Indicators

The company's current market capitalization stands at $2.98 billion, with a total enterprise value of $2.56 billion.

Financial Indicator Value
Price/Sales Ratio 8.12
Forward Price/Earnings -12.37

Dividend Information

The company currently does not pay a dividend, with a dividend yield of 0%.




Key Risks Facing Denali Therapeutics Inc. (DNLI)

Risk Factors Impacting Financial Health

The company faces several critical risk factors that could potentially impact its financial performance and strategic objectives.

Key Operational Risks

Risk Category Potential Impact Severity Level
Clinical Trial Failures Potential loss of $75-120 million per failed program High
Regulatory Compliance Potential FDA rejection risks Medium
Research Pipeline Delays Potential revenue postponement Medium

Financial Risk Assessment

  • Research and development expenses reached $304.8 million in recent fiscal year
  • Cash burn rate approximately $250 million annually
  • Potential funding challenges for ongoing neurological disease research programs

Market and Competitive Risks

Competitive landscape presents significant challenges with multiple emerging biotechnology firms targeting similar neurological disease treatments.

Competitive Risk Potential Consequence
Patent Expiration Revenue reduction potential of 15-25%
Market Entry of Competing Therapies Market share erosion risk

Strategic Risk Mitigation

  • Diversified research portfolio across multiple neurological disease areas
  • Continuous investment in innovative research platforms
  • Strategic partnerships to share development costs

External Market Risks

Macroeconomic factors including potential funding constraints and healthcare policy changes pose additional challenges.




Future Growth Prospects for Denali Therapeutics Inc. (DNLI)

Growth Opportunities

The company's growth potential is anchored in several key strategic areas:

  • Neurodegenerative disease pipeline with 6 clinical-stage programs
  • Total research and development expenses of $342.3 million in 2022
  • Cash and investments totaling $816.9 million as of December 31, 2022
Program Disease Area Development Stage
DNL151 Parkinson's Disease Phase 2
DNL788 Alzheimer's Disease Phase 1
DNL343 ALS Preclinical

Strategic partnerships include collaborations with:

  • Biogen
  • Takeda Pharmaceutical
  • Sanofi

Key competitive advantages include:

  • Proprietary brain shuttle technology
  • Advanced neurodegeneration research platform
  • Robust intellectual property portfolio with over 300 patents

DCF model

Denali Therapeutics Inc. (DNLI) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.